IRCCS Ospedale San Raffaele

Running trials

• Not yet recruiting

  Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies

  NCT07759661· Source

• Not yet recruiting

  A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer

  NCT07610083· Source

• Not yet recruiting

  EUS-Based Artificial Intelligence to Predict Outcomes in Pancreatic Cancer

  NCT07803770· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Source

• Not yet recruiting

  TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells and Inflammatory Bowel Disease

  NCT07740499· Source

• Recruiting

  A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

  NCT07559175· Phase 2· Source

• Not yet recruiting

  DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

  2026-525268-16-00· Phase 2/3· Source

• Not yet recruiting

  Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis

  NCT07571525· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· Source

• Not yet recruiting

  Prospective Perioperative Clinical Registry for Women Undergoing Benign Gynecological Surgery

  NCT07772076· Source

• Not yet recruiting

  Spectral and Ultra High Resolution CT Systems for Non-Invasive Detection of Myocardial Ischemia: Stress CT Perfusion VS. FFR-CT

  NCT07544277· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

  NCT07587242· Phase 3· Source

• Not yet recruiting

  Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables

  NCT07533084· Source

• Not yet recruiting

  ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy

  NCT07597642· Source

• Recruiting

  Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia

  NCT07680803· Phase 2· Source

• Recruiting

  A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· Phase 3· Source

• Active, not recruiting

  The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition

  NCT07796776· Source

• Not yet recruiting

  M1no-Study - Early Identification of Infants With High Type 1 Diabetes Risk for Participation in Primary Prevention Trials

  NCT07670143· Source

• Not yet recruiting

  AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation

  NCT07604727· Source

• Recruiting

  A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

  NCT07700992· Source

• Not yet recruiting

  A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

  NCT07455422· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  Multicenter Study for External Validation of the TB-NET Score

  NCT07903532· Source

• Recruiting

  Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure

  NCT07560982· Source

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Source

• Recruiting

  ATLG Levels in Autologous HSCT for Multiple Sclerosis

  NCT07635693· Source

• Not yet recruiting

  This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life Based on the Treatment Received in the Group of Patients Suffering From Malignant Lesions of the Head and Neck

  NCT07066878· Source

• Active, not recruiting

  Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms

  NCT07825207· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Source

• Not yet recruiting

  Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients

  NCT07526298· Source

• Recruiting

  InRAD Observational Study

  NCT07213700· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Source

• Not yet recruiting

  Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients

  NCT07465458· Source

• Not yet recruiting

  Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease

  NCT07431255· Source

• Recruiting

  A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

  NCT07595653· Source

• Recruiting

  TACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial.

  NCT06887413· Source

• Not yet recruiting

  Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study

  2025-521583-35-00· Phase 2· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Source

• Not yet recruiting

  Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations

  NCT07265895· Source

• Recruiting

  Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

  NCT07330245· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Source

• Recruiting

  Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL

  NCT07774390· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Active, not recruiting

  Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

  NCT07393204· Source

• Recruiting

  A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting

  NCT07220824· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Source

• Recruiting

  Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

  NCT07278921· Source

• Recruiting

  A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

  NCT07203768· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer17 recruiting
• Chronic lymphocytic leukaemia12 recruiting
• Colorectal cancer11 recruiting
• Pancreatic cancer11 recruiting
• Gastric and esophageal cancer10 recruiting
• Heart failure10 recruiting
• Crohn's disease9 recruiting
• Bladder cancer8 recruiting
• Kidney cancer8 recruiting
• Liver and biliary tract cancer8 recruiting
• Prostate cancer8 recruiting
• Ulcerative colitis7 recruiting
• Alzheimer disease6 recruiting
• Diffuse large B-cell lymphoma6 recruiting
• Follicular lymphoma6 recruiting
• Childhood cancers5 recruiting
• Coronary artery disease5 recruiting
• ALS (motor neurone disease)4 recruiting
• Head and neck cancer4 recruiting
• Mantle cell lymphoma4 recruiting
• Metastatic breast cancer4 recruiting
• Neuroendocrine tumours4 recruiting
• Obesity4 recruiting
• Multiple myeloma3 recruiting
• Myasthenia gravis3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Psoriasis3 recruiting
• Acute myeloid leukemia2 recruiting
• Cystic fibrosis2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Endometrial cancer2 recruiting
• Endometriosis2 recruiting
• High blood pressure2 recruiting
• HIV2 recruiting
• Migraine2 recruiting
• Multiple sclerosis2 recruiting
• Parkinson disease2 recruiting
• Polycystic kidney disease2 recruiting
• Psoriatic arthritis2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 1 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Frontotemporal dementia1 recruiting
• Glioblastoma1 recruiting
• Hepatitis B1 recruiting
• Hodgkin lymphoma1 recruiting
• IgA nephropathy1 recruiting
• Lupus (SLE)1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Retinitis pigmentosa1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting
• Thyroid cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study on the Effect of the Intake of a Calcium-bicarbonate Water on Cholesterol Levels

  NCT07026266· Source

• Completed

  BURDEN OF ESOPHAGEAL CANCER IN EOSINOPHILIC ESOPHAGITIS (ESCAPE STUDY)

  NCT07102329· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Source

• Completed

  Platelet Function and Impella Support

  NCT06487091· Source

• Completed

  LOW-PV Continuation

  NCT06752941· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Source

• Completed

  Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study

  2023-509088-26-00· Phase 2· Source

• Completed

  Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options (FOST Switch)

  2023-504192-25-00· Phase 4· Source

• Completed

  A Real-world Study in Participants With Smoldering Multiple Myeloma

  NCT06472778· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Source

• Completed

  Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer

  NCT06195150· Source

• Completed

  A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).

  NCT06196424· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Source

• Completed

  A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  NCT05852691· Phase 2· Source

• Completed

  AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease

  NCT05471245· Source

• Completed

  A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

  NCT05841030· Source

• Terminated

  Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

  NCT05785715· Phase 2· Source

• Withdrawn

  Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients

  NCT04565496· Phase 2· Source

• Completed

  A Study of Vedolizumab in Adults With Crohn's Disease (CD)

  NCT05192863· Source

• Completed

  Artificial Intelligence & Prostate Cancer

  NCT06298305· Source

• Completed

  Immune Activation, Neural Plasticity and Depression

  NCT06306248· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· Source

• Completed

  Extension Study Evaluating The Safety And Tolerability of AMX0035

  NCT05619783· Phase 3· Source

• Completed

  An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

  NCT05616871· Source

• Completed

  Passive Music Listening in Acute Cerebrovascular Disease

  NCT06743412· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Source

• Completed

  Development and Validation of a Comorbidity Index in Crohn's Disease

  NCT05253378· Source

• Terminated

  An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

  NCT04586244· Phase 2· Source

• Completed

  Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry"

  NCT05164640· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

  NCT05081557· Source

• Completed

  A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

  NCT05071664· Phase 2· Source

• Completed

  A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

  NCT04968912· Phase 2· Source

• Recruiting

  Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease

  NCT07013344· Source

• Completed

  AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

  NCT05028660· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Source

• Completed

  Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients

  NCT04832958· Phase 2· Source

• Completed

  Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

  NCT04607837· Phase 2· Source

• Completed

  MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

  NCT04509791· Phase 2· Source

• Recruiting

  Abbott Vascular Medical Device Registry

  NCT04573660· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· Source

• Completed

  A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag

  NCT04567602· Source

• Completed

  Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

  NCT04362072· Phase 4· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Source

Trial sites

• IRCCS Ospedale San Raffaele0 trials
• Deaprtment of Radiology, IRCCS Ospedale San Raffaele1 trial
• Department of Radiology, IRCCS Ospedale San Raffaele1 trial
• DIMER, IRCCS, Ospedale San Raffaele1 trial
• Dipartimento di Oncologia Medica, IRCCS Ospedale San Raffaele1 trial
• Dipartimento di Radiologia, Ospedale San Raffaele1 trial
• Duplicate_Ospedale San Raffaele IRCCS /ID# 2411670 trials
• Endocrinologia Infantile, UOU di Pediatria, IRCCS Ospedale San Raffaele1 trial
• Farmacia (magazzino ricevimento merc), IRCCS Ospedale San Raffaele1 trial
• Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital2 trials
• Ginecologia e Ostetricia, IRCCS Ospedale San Raffaele1 trial
• Hospital San Raffaele2 trials
• Hospital San Raffaele, IRCCS, Unit of Immunology, Rheumatology, Allergy and Rare Diseases1 trial
• IRCCS Ospedale San Raffaele121 trials
• Irccs Ospedale San Raffaele - Area Unica Di Terapia Intensiva Cardiologica E Cch1 trial
• IRCCS Ospedale San Raffaele - Cognitive Disorders and Dementia Center (CDCD)1 trial
• IRCCS Ospedale San Raffaele - Endoscopia Biliopancreatica1 trial
• Irccs Ospedale San Raffaele, Gastroenterologia/Ibd Unit, Settore G Piano -10 trials
• IRCCS Ospedale San Raffaele (HSR) - Dipartimento Di Neurologia0 trials
• IRCCS Ospedale San Raffaele /ID# 2255550 trials
• IRCCS Ospedale San Raffaele /ID# 2269730 trials
• IRCCS Ospedale San Raffaele /ID# 2286690 trials
• IRCCS Ospedale San Raffaele /ID# 2425830 trials
• IRCCS Ospedale San Raffaele /ID# 2515621 trial
• IRCCS Ospedale San Raffaele /ID# 2529100 trials
• IRCCS Ospedale San Raffaele /ID# 2535311 trial
• IRCCS Ospedale San Raffaele /ID# 2543760 trials
• IRCCS Ospedale San Raffaele /ID# 2552851 trial
• IRCCS Ospedale San Raffaele /ID# 2564040 trials
• IRCCS Ospedale San Raffaele /ID# 2585920 trials
• IRCCS Ospedale San Raffaele /ID# 2610581 trial
• IRCCS Ospedale San Raffaele /ID# 2630350 trials
• IRCCS Ospedale San Raffaele /ID# 2630640 trials
• IRCCS Ospedale San Raffaele /ID# 2651271 trial
• IRCCS Ospedale San Raffaele /ID# 2659510 trials
• IRCCS Ospedale San Raffaele /ID# 2662121 trial
• IRCCS Ospedale San Raffaele /ID# 2684261 trial
• IRCCS Ospedale San Raffaele /ID# 2694750 trials
• IRCCS Ospedale San Raffaele /ID# 2731531 trial
• IRCCS Ospedale San Raffaele /ID# 2744581 trial
• IRCCS Ospedale San Raffaele /ID# 2745160 trials
• IRCCS Ospedale San Raffaele /ID# 2747891 trial
• IRCCS Ospedale San Raffaele /ID# 2767930 trials
• IRCCS Ospedale San Raffaele /ID# 2773421 trial
• IRCCS Ospedale San Raffaele - Neurology and Neurophysiology Unit1 trial
• IRCCS Ospedale San Raffaele, Oculistica0 trials
• IRCCS Ospedale San Raffaele, San Raffaele Hospital1 trial
• IRCCS Ospedale San Raffaele (Site 0171)1 trial
• IRCCS Ospedale San Raffaele (Site 0362)0 trials
• IRCCS Ospedale San Raffaele (Site 0539)0 trials
• IRCCS Ospedale San Raffaele (Site 0596)0 trials
• IRCCS Ospedale San Raffaele (Site 1402)1 trial
• IRCCS Ospedale San Raffaele (Site 1409)1 trial
• IRCCS Ospedale San Raffaele (Site 1500)0 trials
• IRCCS Ospedale San Raffaele (Site 2012)0 trials
• IRCCS Ospedale San Raffaele (Site 2130)0 trials
• IRCCS Ospedale San Raffaele (Site 4600)1 trial
• IRCCS Ospedale San Raffaele-Site Number : 38000010 trials
• IRCCS Ospedale San Raffaele-Site Number : 38000060 trials
• IRCCS Ospedale San Raffaele SRL1 trial
• IRCCS Ospedale San Raffaele, Unita di Gastroenterologia1 trial
• IRCCS Ospedale San Raffaele - Università Vita-Salute San Raffaele di Milano1 trial
• IRCCS Ospedale San Raffaele, U.O. Farmacia Studi Clinici0 trials
• IRCCS Ospedale San Raffaele - U.O. Ginecologia e Ostetricia1 trial
• IRCCS Ospedale San Raffaele, URI (Urological Research Institute)0 trials
• IRCCS Ospedale San Raffaele ,Via Olgettina 601 trial
• IRCCS San Raffaele Hospital14 trials
• IRCCS San Raffaele Hospital, Milano1 trial
• Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele7 trials
• Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele Hospital0 trials
• Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) - Ospedale San Raffaele (Hsr) (Istituto1 trial
• Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario Sa0 trials
• Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)1 trial
• Istituto Scientifico Universitario San Raffaele1 trial
• Ospedale San Raffaele79 trials
• Ospedale San Raffaele - 23070 trials
• Ospedale San Raffaele - Aritmologia1 trial
• Ospedale San Raffaele - Chirurgia Gastroenterologica1 trial
• Ospedale San Raffaele (HSR) Instituto Scientifico Universitario San Raffaele0 trials
• Ospedale San Raffaele (HSR) - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)0 trials
• Ospedale San Raffaele, IRCCS2 trials
• Ospedale San Raffaele IRCCS /ID# 1142-05231 trial
• Ospedale San Raffaele IRCCS /ID# 1252611 trial
• Ospedale San Raffaele IRCCS /ID# 2290591 trial
• Ospedale San Raffaele, IRCCS - Oncologia Medica2 trials
• Ospedale San Raffaele, Merz Investigational Site #03900270 trials
• Ospedale San Raffaele - Milano2 trials
• Ospedale San Raffaele. (Site 0171)0 trials
• Ospedale San Raffaele. (Site 0194)0 trials
• Ospedale San Raffaele (Site #0907)0 trials
• Ospedale San Raffaele. (Site 1104)0 trials
• Ospedale San Raffaele. (Site 1305)0 trials
• Ospedale San Raffaele. (Site 1502)1 trial
• Ospedale San Raffaele. (Site 2106)0 trials
• Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo3 trials
• Ospedale San Raffaele - U.O. di Oncologia Medica1 trial
• Ospedale San Raffale, IRCCS0 trials
• Pediatric Immunohematology Unit, IRCCS Ospedale San Raffaele1 trial
• Radiation oncology unit, Ospedale San Raffaele1 trial
• San Raffaele Hospital39 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure149 works · 15 trials
• Bladder cancer139 works · 15 trials
• Prostate cancer136 works · 14 trials
• Multiple sclerosis120 works · 5 trials
• Ulcerative colitis108 works · 14 trials
• Crohn's disease97 works · 15 trials
• Liver and biliary tract cancer86 works · 9 trials
• Systemic sclerosis (scleroderma)81 works · 0 trials
• HIV79 works · 3 trials
• Kidney cancer76 works · 11 trials
• Pancreatic cancer58 works · 14 trials
• Type 1 diabetes47 works · 4 trials
• Chronic kidney disease47 works · 3 trials
• Depression35 works · 4 trials
• Bipolar disorder31 works · 0 trials
• Chronic lymphocytic leukaemia30 works · 16 trials
• Acute myeloid leukemia27 works · 4 trials
• Macular degeneration25 works · 2 trials
• Neuroendocrine tumours23 works · 6 trials
• Lupus (SLE)22 works · 4 trials
• Migraine20 works · 3 trials
• Diabetic eye disease18 works · 2 trials
• ALS (motor neurone disease)16 works · 6 trials
• Metastatic breast cancer14 works · 15 trials
• Pulmonary arterial hypertension13 works · 1 trials
• Acute lymphoblastic leukaemia13 works · 1 trials
• Endometriosis13 works · 2 trials
• Neuromyelitis optica (NMOSD)11 works · 1 trials
• Mantle cell lymphoma10 works · 4 trials
• Polycystic kidney disease10 works · 2 trials